Biota Pharmaceuticals Inc  

(Public, NASDAQ:BOTA)   Watch this stock  
Find more results for BOTA
-0.01 (-0.48%)
Aug 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.06 - 2.15
52 week 1.94 - 3.00
Open 2.06
Vol / Avg. 38,358.00/55,730.00
Mkt cap 73.06M
P/E     -
Div/yield     -
EPS -0.27
Shares 35.12M
Beta 0.94
Inst. own 46%
Nov 11, 2015
Biota Pharmaceuticals Inc Annual Shareholders Meeting (Estimated) - 9:00AM EST - Add to calendar
Sep 24, 2015
Q4 2015 Biota Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Sep 9, 2015
Biota Pharmaceuticals Inc at Rodman & Renshaw Global Investment Conference - 4:15PM EDT - Add to calendar
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 20.34% -16.01%
Operating margin 18.64% -16.74%
EBITD margin - -11.21%
Return on average assets 5.28% -11.01%
Return on average equity 5.87% -14.20%
Employees 66 -
CDP Score - -


2500 Northwinds Pkwy Ste 100
ALPHARETTA, GA 30009-2248
United States - Map
+1-678-2213343 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Biota Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing oral, small molecule compounds to treat respiratory-related viral infections. The Company has four product candidates in development that address viral infections, which inlcude Vapendavir, an oral treatment for human rhinovirus infections in moderate-to-severe asthmatics; AP611074, a topical treatment for genital warts caused by human papillomavirus (HPV) types 6 and 11; BTA-C585, an oral fusion inhibitor in development for the treatment of respiratory syncytial virus infections, and laninamivir octanoate, a one-time, inhaled treatment for influenza A and B infections. In addition, the Company's Zanamivir is marketed around the world as Relenza for the prevention and treatment of Influenza A and B. Its Laninamivir Octanoate, LANI, an octanoyl ester pro-drug of laninamivir, is marketed in Japan as Inavir for the treatment and prophylaxis of influenza A and B infections.

Officers and directors

Peter J. Azzarello CPA Chief Accounting Officer, Vice President - Finance
Age: 43
Bio & Compensation  - Reuters
Russell H. Plumb Executive Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Joseph M. Patti Ph.D. President, Chief Executive Officer, Director
Age: 50
Bio & Compensation  - Reuters
James Charles Fox Ph.D. Lead Independent Director
Age: 63
Bio & Compensation  - Reuters
Geoffrey F. Cox Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Michael R. Dougherty Independent Director
Age: 57
Bio & Compensation  - Reuters
John P. Richard Independent Director
Age: 57
Bio & Compensation  - Reuters
Anne M. VanLent Independent Director
Age: 67
Bio & Compensation  - Reuters